Karat A B, Jeevaratnam A, Karat S, Rao P S
Br Med J. 1970 Jan 24;1(5690):198-200. doi: 10.1136/bmj.1.5690.198.
A double-blind controlled trial in 24 lepromatous leprosy patients in reaction showed that clofazimine (Lamprene) controlled symptoms of erythema nodosum leprosum reaction in lepromatous leprosy better than prednisolone. Clofazimine also appeared to be significantly superior in preventing recurrence once the reaction had been controlled. There was a statistically significant rise in serum albumin among inpatients on clofazimine as compared with patients on prednisolone, but no difference in terms of neurological status, bacterial index, morphological index, and renal functions. Red/black hyperpigmentation was seen among practically all patients on clofazimine. No other side-effects or deleterious systemic effects were observed.
一项针对24例麻风反应期瘤型麻风患者的双盲对照试验表明，氯法齐明（氯苯吩嗪）在控制瘤型麻风结节性红斑反应症状方面比泼尼松龙效果更好。在反应得到控制后，氯法齐明在预防复发方面似乎也显著更优。与服用泼尼松龙的患者相比，服用氯法齐明的住院患者血清白蛋白有统计学意义的升高，但在神经状态、细菌指数、形态学指数和肾功能方面无差异。几乎所有服用氯法齐明的患者都出现了红/黑色色素沉着。未观察到其他副作用或有害的全身影响。
